SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as traders discuss its potential short squeeze, fueled by high short interest and substantial open call option interest, with some highlighting the company's AI developments and Google backing. Community members are actively debating potential price movements, resistance levels, and the impact of short sellers, while noting analyst price targets. Some see $WULF as undervalued compared to peers in the AI data center space.

Aqua Metals, Inc. engages in reinventing metal recycling technologies. Its patented technology, AquaRefining, replaces polluting furnaces and hazardous chemicals with electricity-powered electroplating to recover valuable metals and materials from spent batteries with higher purity, lower emissions, and minimal waste. The company was founded by Stephen R. Clarke, Thomas Murphy, and Selwyn Mould on June 20, 2014 and is headquartered in Reno, NV.

Aqua Metals Inc

AQMS is trending due to its position as a low-float critical metals play, experiencing a significant surge that has captured the attention of the community. Traders are actively discussing profit-taking strategies, potential for further gains, and comparing it to other stocks in the sector. Some are speculating about a potential offering, while others see a continuation of the upward trend.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders react to a former president's social media posts regarding trade relations with China, specifically related to cooking oil and soybeans. The community is actively discussing the market's sensitivity to these tweets, questioning whether such news warrants the market's reaction and also debating potential market manipulation.

Avalon Holdings Corp. engages in the provision of waste management services to industrial, commercial, municipal, and governmental customers. It operates through the Waste Management Services and Golf and Related Operations segments. The Waste Management Services segment offers waste disposal brokerage and management services, captive landfill management operations, and salt water injection well operations. The Golf and Related Operations segment focuses on the operation and management of golf courses and related country clubs, hotels and resort amenities, athletic centers, and travel agencies. The company was founded on April 30, 1998 and is headquartered in Warren, OH.

Avalon Holdings Corp. - Ordinary Shares - Class A

Avalon Holdings Corp. 

AWX is trending due to increased community interest and bullish sentiment, with many highlighting its low float and potential for significant upward movement. Discussions revolve around the stock's similarity to other recent high-flying low floaters in the waste management sector, such as $AQMS and $GWAV. Some traders are looking for quick gains while others focus on the company's long-term value.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

NVTS is surging due to progress on its 800V GaN and SiC power devices for NVIDIA's AI factory computing platforms, sparking excitement about its role in AI infrastructure. The community is closely watching for a potential short squeeze, with many expressing bullish sentiment and targeting higher price levels. Some investors are debating whether to chase the rally or wait for a pullback.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines ($LUNR) is trending as the community focuses on the company's potential for profit and upcoming missions. The stock is experiencing increased attention amid discussions about a possible short squeeze and anticipation of an upcoming earnings report. Bullish sentiment centers around the belief that $LUNR is undervalued, especially compared to other companies in the space sector.

Greenwave Technology Solutions, Inc. is an emerging growth company, which engages in recycling ferrous metal. It also recycles nonferrous metals including aluminum, copper, stainless steel, nickel, brass, titanium, lead, alloys, and mixed metal products. The company was founded on April 26, 2013 and is headquartered in Chesapeake, VA.

Greenwave Technology Solutions Inc

GWAV is trending due to a surge in price and volume, sparking discussions of a potential short squeeze and comparisons to other recently volatile stocks. Community members are actively debating whether to hold or take profits, while some express concern over the company's fundamentals and past history of dilution. The stock's movement appears to be related to a broader interest in recycling and critical mineral companies.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as the Russell 2000 ETF hits new highs, with community members discussing potential catalysts and resistance levels around $250. Bullish sentiment is fueled by the ETF's impressive move from its low of day, leading to speculation about a continued rally. Some traders are taking profits and hedging positions, while others express concerns about overbought conditions and potential pullbacks.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as traders discuss a potential breakout and compare it to $HOOD, focusing on its growth potential and international expansion. Optimism is fueled by technical indicators like bullish candlestick patterns and discussions around options expiration, with some anticipating a significant price increase. Community members are debating whether the stock is undervalued and poised for a rally, while others express concern about recent price action and volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to market reactions to escalating trade tensions with China, particularly after a statement regarding potential restrictions on cooking oil imports. Community discussions revolve around the perceived market manipulation and the impact of these trade war escalations on tech stocks. The broader context includes concerns about potential economic consequences and the Federal Reserve's response to these developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Johnson &amp; Johnson’s (J&amp;J) stock&nbsp;fell 0.4% in premarket trade on Tuesday as investors positioned ahead of the healthcare giant’s quarterly results due Tuesday, with focus on its medical devices business, drug pipeline, and tariff exposure.The company is expected to post revenue of $23.76 billion, nearly flat from last year's $23.74 billion, according to estimates from Koyfin. Adjusted EPS is expected to be $2.76, down from $2.77 a year ago. EBITDA is expected to come in 0.6% lower at $8.58 billion, while EBIT is expected to tick up 0.5% to $8 billion.J&amp;J shares trade near $190.90, close to their 12-month average price target of $187.49, implying limited near-term upside. Analysts maintain a broadly positive stance, with 10 rating it a ‘Buy,’ 11 a ‘Hold,’ and two a ‘Strong Buy.’In July, J&amp;J cut its tariff-related cost forecast for the year to $200 million, down from $400 million, citing lower-than-expected impact on its medical devices business after the Trump administration paused some China and EU duties. CFO Joe Wolk said the company absorbed the costs while still raising its profit outlook, describing the tariff effect as “minimal.”Growth in the medtech unit is expected to be a bright spot, driven by sales from cardiovascular products such as Varipulse and Trupulse, and Abiomed’s Impella heart pumps. J&amp;J said in July that robotic surgery and cardiovascular devices will be the key engines of growth for its medtech unit.Attention will also be on Carvykti, J&amp;J’s blood cancer therapy developed with Legend Biotech, which recently received a U.S. FDA label update adding a black box warning for a rare intestinal inflammation. Regulators said the therapy’s benefits still outweigh risks, highlighting longer patient survival versus standard treatments.In immunology, the company faces renewed pressure from biosimilar competition to its top-selling drug Stelara. To offset potential declines, J&amp;J has been pursuing acquisitions, including reported talks to acquire Protagonist Therapeutics, its partner on an oral therapy for plaque psoriasis and ulcerative colitis. A deal would add late-stage drug Rusfertide, seen as complementary to J&amp;J’s immunology and oncology portfolios.Legal overhangs persist after a $966 million jury verdict in California earlier this month tied to talc-related cancer claims, which J&amp;J plans to appeal. The company maintains&nbsp;that its products are safe and asbestos-free.On Stocktwits, retail sentiment for J&amp;J was ‘extremely bullish’ amid a&nbsp; 2,200% surge in 24-hour message volume.One user predicted that J&amp;J shares could climb to the $196–$200 range after earnings, while others speculated the biotech might announce an Altimmune acquisition during Tuesday’s earnings call.<stembedurl>https://stocktwits.com/Wenwenwenwenwenwen/message/632192878</stembedurl><stembedurl>https://stocktwits.com/Ad7777/message/632156784</stembedurl><stembedurl>https://stocktwits.com/namv/message/632137184</stembedurl><a href="https://stocktwits.com/symbol/JNJ">J&amp;J’s stock</a> has risen 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

JNJ beat third-quarter earnings estimates but lowered guidance for the year 

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Equity

BMO Capital raised its price target on Protagonist Therapeutics to $112 from $72 and maintained an 'Outperform' rating, citing reports that Johnson &amp; Johnson may acquire the biotech firm.&nbsp;In a note to investors, the firm said its updated model better reflects the potential value of Protagonist’s two key drug assets, Rusfertide and Icotrokinra, for an acquirer, and that the market is “underpricing what Protagonist could be worth.”<a href="https://stocktwits.com/symbol/PTGX">Protagonist Therapeutics’ stock</a> fell 9% to $79.17 on Monday, marking its worst trading session in more than three months, before edging up 0.1% in after-hours trade.J&amp;J is reportedly in talks to buy Protagonist in a deal that would strengthen its existing partnership on an oral therapy for immune diseases such as plaque psoriasis and ulcerative colitis, for which J&amp;J already holds exclusive commercialization rights. The healthcare giant also owns nearly 4% of Protagonist’s shares, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/johnson-johnson-in-talks-to-buy-protagonist-therapeutics-38e0b69d">reported</a> last week.An acquisition would give J&amp;J access to Rusfertide, which has shown promise in late-stage trials for polycythemia vera, a rare blood cancer. Both Rusfertide and Icotrokinra would complement J&amp;J’s existing portfolio of immune and oncology treatments.Meanwhile, J&amp;J is seeking acquisitions to offset declining sales of its blockbuster immune-disease drug Stelara, now facing biosimilar competition.On Stocktwits, retail sentiment was ‘bullish’ for Protagonist Therapeutics with ‘extremely high’ message volume, while sentiment toward Johnson &amp; Johnson was ‘extremely bullish’ amid normal activity.One user called the pullback in Protagonist a “great buying opportunity,” arguing that retail investors were mistaken to think the company would sell for less than $5 billion.&nbsp;<stembedurl>https://stocktwits.com/outlawinvestor1/message/632143522</stembedurl>On the other hand, another user predicted the potential deal could value Protagonist shares&nbsp;at around $35.<stembedurl>https://stocktwits.com/Fugazi_/message/632134508</stembedurl>So far this year, Protagonist shares have more than doubled in value, while&nbsp;<a href="https://stocktwits.com/symbol/JNJ">Johnson &amp; Johnson shares</a> have gained about 35%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

So far this year, Protagonist shares (PTGX) have more than doubled in value, while Johnson & Johnson shares (JNJ) have gained about 35%. (Photo credit: Getty Images)

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In

The research firm said its higher target better reflects the value of Protagonist’s key drug assets, Rusfertide and Icotrokinra.

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal

PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.

RTW Investments' Rod Wong: Expect more deals in biotech space

Rod Wong, RTW Investments CIO & Managing Director, joins CNBC's 'Money Movers' to discuss J&J's reported interest in buying Protagonist Therapeutics, whether he expects more consolidation in the...

JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra

J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Protagonist Therapeutics Set to Join S&P SmallCap 600

Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK, June 27, 2024 NEW YORK, June 27, 2024 /PRNewswire/ -- Protagonist...

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

PTGX
Protagonist Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PTGX News

PTGXProtagonist Therapeutics Inc